Ankylosing spondylitis

| Main Article
| Discussion
| Related Articles  [?]
| Bibliography  [?]
| External Links  [?]
| Citable Version  [?]

|
|
|
|
|
|
|
|

This editable Main Article is under development and subject to a disclaimer.

[edit intro]

In medicine and rheumatology, ankylosing spondylitis is an "inflammatory joint disease affecting the spine. It occurs predominantly in young males and produces pain and stiffness as a result of inflammation of the sacroiliac, intervertebral, and costovertebral joints. Etiology is unknown."[1][2]

## Treatment[edit]

Inhibitors of tumor necrosis factor-alpha can benefit according to a meta-analysis.[3] For example, TNFR-Fc fusion protein (etanercept - pronounced et a ner' set) blocks the activity of tumor necrosis factor-alpha.[4] and may help patients with ankylosing spondylitis.[5][6]

## References[edit]

1. ↑ Anonymous (2025), Ankylosing spondylitis (English). Medical Subject Headings. U.S. National Library of Medicine.
2. ↑ Braun J, Sieper J (April 2007). "Ankylosing spondylitis". Lancet 369 (9570): 1379–90. DOI:10.1016/S0140-6736(07)60635-7. PMID 17448825. Research Blogging.
3. ↑ McLeod C, Bagust A, Boland A, et al (August 2007). "Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation". Health Technol Assess 11 (28): 1–158, iii–iv. PMID 17651658. [e]
4. ↑ The most up-to-date information about Etanercept and other drugs can be found at the following sites.
* Etanercept \-  FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
* Etanercept \- Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
* Etanercept \- Detailed information from DrugBank.
5. ↑ Gorman JD, Sack KE, Davis JC (May 2002). "Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha". N. Engl. J. Med. 346 (18): 1349–56. DOI:10.1056/NEJMoa012664. PMID 11986408. Research Blogging.
6. ↑ Furst DE, Breedveld FC, Kalden JR, et al (November 2007). "Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007". Ann. Rheum. Dis. 66 Suppl 3: iii2–22. DOI:10.1136/ard.2007.081430. PMID 17934088. Research Blogging.